Advertisement

Search Results for "Inosine Ms Clinical Trial"

13:00 EDT 19th June 2013 | BioPortfolio

Original Source: Treatment of Multiple Sclerosis Using Over the Counter Inosine

The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting Multiple Sclerosis (RRMS) and secondary progressive Multiple Sclerosis (MS).

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...

Clinical Approvals - news, views, reports and blogs

Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and eff...

Xofigo (radium-223 dichloride)

New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases. Xofigo shown in a pivotal phase III trial to significantly improve overall survival. Xofigo® with...

Vitamin E Toxicity

Research has not found any adverse effects from consuming vitamin E in food. However, high doses of alpha-tocopherol supplements can cause hemorrhage and interrupt blood coagulation in animals, and...

Contract Research Organization news

A contract research organization, also called a clinical research organization, (CRO) is a service organization that provides support to the pharmaceutical and biotechnology industries in the form o...

Matching News

Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature

Yanick Crow and colleagues show that mutations in ADAR1 cause the autoimmune disorder Aicardi-Goutières syndrome, accompanied by upregulation of interferon-stimulated genes. ADAR1 encodes an enzyme t...

Biotron completes clinical stage of HIV clinical trial

Biotron Limited (BIT) has completed the clinical stage of a landmark phase 1b/2a proof-of-concept human trial of its lead HIV drug candidate, BIT225. The placebo-controlled, double-blinded study was u...

A Tough Push For Clinical Trial Disclosure In Europe

As the debate over clinical trial transparency heats up, the lead legislator for the Environment, Public Health and Food Safety Committee in the European Parliament wants to toughen proposed legislati...

From Clinical Trial to Publication Takes Close to 2 Years

The median time from completion of a clinical trial to publication of results in a peer-reviewed journal is 21 months, although the goal is to report clinical trial results within a year. Medscape M...

Research on clinical trial issues for biosimilars

Period: September to December 2012 In order to demonstrate comparability between a biosimilar and its reference product, EMA recommends that the clinical trial should make it possible to detect a...

FDA Gets New Authority Over Clinical Trial Reporting

Here is an interesting development in the ongoing controversy over reporting clinical trial data in all its glory to the federal government. The US Department of Health & Human Services has trans...

Trial And Error: India Sets Compensation Rules For Clinical Trial Victims; Warns Cancellation In Cases Of Violations

A government notification laid down a structured compensation plan for clinical trial victims. The move aims to tighten rules for clinical trials in an industry under attack from health activists and...

Trial And Error: India Sets Compensation Rules For Clinical Trial Victims, Warns Cancellation In Cases Of Violations

A government notification laid down a structured compensation plan for clinical trial victims. The move aims to tighten rules for clinical trials in an industry under attack from health activists and...

Matching PubMed Articles

De novo engineering and metabolic flux analysis of inosine biosynthesis in Bacillus subtilis.

Wild-type B. subtilis strain W168 was de novo engineered for inosine biosynthesis. Inactivation of deoD and purA led to 0.15 ± 0.04 and 6.44 ± 0.39 g inosine/l yields, respectively. The deoD pu...

The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A 2A receptors.

Inosine is an endogenous purine nucleoside, which is formed during the breakdown of adenosine. The adenosinergic system was already described as capable of modulating mood in preclinical models; we no...

Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A(2) receptors.

Adenosine and its metabolite, inosine, have been described as molecules that participate in regulation of inflammatory response. The aim of this study was to investigate the effect of adenosine and in...

Synthesis of 2'-Substituted Inosine Analogs via Unusual Masking of the 6-Hydroxyl Group.

2'-Modified inosine analogs have been synthesized from 6-chloropurine riboside via 6-dimethylaminopurine or 6-benzyloxypurine intermediates. The dimethylaminopurine intermediate was obtained via an un...

Low-Temperature NMR Studies on Inosine Wobble Base Pairs.

Base pairs formed by the inosine nucleoside (I) play an important role in many physiological processes as well as in various DNA technologies. Relative stabilities and favored base pair geometries of...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement